Consolidated Financial Results for the Six-month Period Ended September 30, 2024

On October 29, 2024 NEC reported consolidated financial Results for the Six-month Period Ended September 30, 2024 (Filing, 3 mnth, SEP 30, NEC, 2024, OCT 29, 2024, View Source [SID1234654128]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


Celaid raised an additional 140 million yen from Kobe University Capital and Techno Science

On October 29, 2024 Celaid Therapeutics reported that it has received a total of 140 million yen in additional Series A funding from KUC1 Investment Limited Partnership (with GP investment from Kobe University Capital Co., Ltd. and SBI University Venture Support Co., Ltd.) and Techno Science Co., Ltd (Press release, Celaid Therapeutics, OCT 29, 2024, View Source [SID1234649810]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Our company has been part of the Kobe Biomedical Innovation Cluster since July 2022, and in the same year, our business was selected for the Kobe Biomedical Innovation Cluster Gap Fund Grant. We have been actively participating as a member of the Kobe Biomedical Innovation Cluster since then. Recently, we have also initiated a joint research project with the Kobe Biomedical Innovation Cluster (March 28, 2024) and are advancing research and development of cell therapy for ischemic diseases as a further clinical application of hematopoietic stem cells. In recognition of our progress in pipeline development and platform business, as well as our activities in Kobe, we have now received new investment from the fund managed by Kobe University Capital Co., Ltd.

Additionally, we have received further investment from our existing investor, Techno Science Co., Ltd., bringing our total Series A funding to 1.1 billion yen (excluding grants). With this funding, we expect to further accelerate our pipeline development and platform business activities.

As a leading hematopoietic stem cell company originating from a Japanese university, we will continue to promote the development of hematopoietic stem cell pipelines and platform technologies.

Leidos Reports Strong Third Quarter 2024 Results and Raises Full-Year Guidance

On October 29, 2024 Leidos Holdings, Inc. (NYSE: LDOS) reported financial results for the third quarter of fiscal year 2024 (Press release, Leidos, OCT 29, 2024, View Source [SID1234649390]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Continued improvement in operating performance across all segments drove excellent revenue growth, record margins for net income and adjusted EBITDA, substantial earnings growth, strong cash flow, and robust bookings," said Leidos Chief Executive Officer Tom Bell. "These results demonstrate clearly how our collaborative and innovative workforce is focused on consistent execution for our customers and shareholders. With a healthy balance sheet, improving business development performance, and emerging ‘North Star’ strategy, Leidos is well positioned to deliver robust and sustainable returns as we move forward."

Third Quarter 2024 Earnings Teleconference

On October 29, 2024 Pfizer reported Third Quarter 2024 Earnings presentation (Presentation, Pfizer, OCT 29, 2024, View Source [SID1234649025]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


2024 Third Quarter Financial and
Corporate Update

On October 29, 2024 Incyte reported Third Quarter Financial and Corporate Update (Presentation, Incyte, OCT 29, 2024, View Source [SID1234647806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!